Participation in any clinical study being conducted at a BluePearl pet hospital requires a referral from your family veterinarian. If you and your veterinarian are interested in learning more about enrollment in one of our active studies, please have your family veterinarian contact the doctor conducting the study.
**We are sorry, but we cannot provide information directly to pet owners about our clinical trials.
CURRENT CANINE STUDIES
- Study Name: Chronic Enteropathy
- Location: Southfield, MI and Blaine, MN
- Purpose: Determine the effect of dietary regulation on canine patients with chronic enteropathy. This study will also potentially provide insight into biomarkers of canine GI disease.
- Study Name: Elbow Dysplasia/Osteoarthritis – Pain Management
- Location: Conshohocken, PA
- Purpose: Evaluate the tolerability, safety and effectiveness of a medication administered by intra-articular injection in client-owned dogs with this condition.
- Study Name: Inflammatory Bowel Disease
- Locations: Overland Park, KS; Virginia Beach, VA
- Purpose: Evaluate the safety and efficacy of a new investigational drug for the management of canine inflammatory bowel disease (IBD).
- Study Name: Splenic Hemangiosarcoma
- Location: Midvale, UT
- Purpose: Compare the effects of two drug therapies (doxorubicin paired with immunotherapy vs. doxorubicin paired with placebo) on the progression free survival time of canine hemangiosarcoma patients after splenectomy.
- Study Name: Transitional Cell Carcinoma
- Locations:Overland Park, KS; Southfield, MI; Midvale, UT
- Purpose: Evaluate the safety and preliminary pain management and potential anti-cancer effect of a novel therapy in dogs with bladder transitional cell carcinoma (TCC).
CURRENT FELINE STUDIES
- Study Name: Diabetes
- Location: Overland Park, KS
- Purpose: Evaluate a new, oral investigational medication that may help feline diabetes mellitus patients and their owners have a once daily treatment choice.
Previous Clinical Studies
Below are clinical studies in which our hospitals and specialists were previously involved. These studies are now closed to enrollment.
- Acute Abdomen Syndrome – C-Reactive Protein (CRP)
- Addison’s Disease – new medication
- Atopic Dermatitis – new medication
- B-Cell Lymphoma – chemotherapy protocol
- Chemotherapy – Evaluation with acupuncture and herbal medicine
- Chemotherapy-Induced Diarrhea – new medication
- Congestive Heart Failure – treatment of associated pulmonary edema and cardiomegaly
- Diabetes – new medication
- Heart Disease – new medication
- Hip Surgery or Limb Amputation – pain reduction
- Hypothyroidism – new medication
- Lymphoma – clinical device to inject cancer drugs
- Lymphoma, B-cell – clinical device to inject cancer drugs
- Lymphoma – therapeutic agent
- Lymphoma, T-cell – immunotherapy chemotherapy protocol
- Lymphoma, T- and B-cell – MAb therapeutic treatment
- Mast Cell Tumors – therapeutic agent
- Melanoma and Mast Cell Tumors – immunotherapy
- Oncology Appetite and Quality-of-Life Survey
- Osteosarcoma – vaccine
- Pain Control Post Cranial Cruciate Ligament or Medial Patellar Luxation Surgery – new medication
- Pain Control Post Cranial Cruciate Ligament Surgery – new medication
- Palladia® Chemotherapy-Induced Diarrhea – medication safety
- Seizures – medication
- Seizures Associated with Idiopathic Epilepsy – medications
- Solid Tumors in Dogs – therapeutic agent
- Soft Tissue Sarcomas – therapeutic agent
- Thrombocytopenia – new platelet product
- Anemia of Chronic Kidney Disease – new medication
- Anemia with any Neoplasia – new medication
- Diabetes Mellitus – new oral medication
- Diabetes Mellitus – newly diagnosed – medication
- Emesis Induction – Effective and Safe
- IRIS Stage 3 Chronic Kidney Disease